administering to the subject an effective amount of a compound that stimulates bone formation and inhibits bone resorption, wherein said compound is an agonist of a cannabinoid receptor and wherein said subject having a bone disease or condition is a subject having a disease or condition selected from the group consisting of periodontal disease or defect,
osteolytic bone disease other than osteoporosis, post-plastic surgery, post-orthopedic implantation, post-dental implantation, age - related osteoporosis, osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes - related osteoporosis, osteoporosis associated with depression, osteoporosis associated with hypogonadism and glucocorticoid - related osteoporosis.
Not exact matches
Tumor cells metastasized to
bone modify the activity of these cells and, depending on the type of cancer, cause osteoblastic or
osteolytic changes.
In the
bone metastatic microenvironment, the crosstalk between metastasized cancer cells and the surrounding
bone cells is critical for the formation of the osteoblastic or
osteolytic phenotype.
ADAMTS1 and MMP1 proteolytically engage EGF - like ligands in an
osteolytic signaling cascade for
bone metastasis
These results demonstrate that ABL kinase activity is required for
osteolytic metastasis in breast cancer and suggest that pharmacological inhibition of the ABL kinases may be an effective treatment for
bone metastasis.
For most patients with breast cancer,
bone metastases are predominantly
osteolytic.
Lesions can be either osteoproliferative (enlarged fuzzy areas on
bone) or
osteolytic (holes in
bone).